TickerSparkInvestor Intelligence
TickerSparkInvestor Intelligence
Community
Main Feed
Today's Market Intel
Top Stocks
AI-Curated Stock Lists
IPO Calendar
Upcoming Listings
Stock Teasers
The Stock Behind the Promo
Trending Stocks
Today's Big Movers
Earnings Coverage
Flashes & Deep Dives
Macro Updates
Economy & Markets
Stock Reports
AI Research Reports
Commentary
Opinionated Stock Takes
Custom Reports
Stock Deep Dives · Free to Try
AI Analyst
Agentic Chat · Free to Try
Watchlist
Track Your Stocks · Free
Spark Charts
AI Technical Analysis · Free to Try
Intel Dashboard
Daily Trade Ideas
Trade Tracker
AI-Managed Portfolio · Pro
My Portfolio
Brokerage Connected · Pro
Custom Reports
Stock Deep Dives
AI Analyst
Agentic Chat
Watchlist
Your Stocks & Notes
Spark Charts
AI Technical Analysis
Intel Dashboard
Daily Trade Ideas
Trade Tracker
AI-Managed Portfolio
My Portfolio
Brokerage Connected
Account
Plan, Billing & Appearance
Log inCreate Account
← Back to TickerSpark
▌Earnings Flash·October 29, 2026

Bristol-Myers Squibb Company (BMY) slips despite earnings beats

Bristol-Myers Squibb Company (BMY) slips 0.6% even after posting earnings beats, as investors weigh the latest results against broader market sentiment.

Earnings FlashBMYHealthcareDrug Manufacturers - General
By TickerSpark·October 29, 2026·2 min read
Bristol-Myers Squibb Company (BMY) slips despite earnings beats
▌Key Takeaway
Bristol-Myers Squibb (BMY) delivered a clean earnings beat, posting $1.35 in EPS versus $1.10 expected and $13.07 billion in revenue versus $12.72 billion forecast. Even so, the stock fell 0.61% to $60.20, signaling that investors want more clarity on whether this performance is sustainable beyond the headline beat.

Bristol-Myers Squibb Company (BMY) Earnings Beat, Stock Slips

Bristol-Myers Squibb Company (BMY) beat estimates with $1.35 EPS and $13.07B in revenue versus $1.10 and $12.72B, yet the stock slipped 0.61% to $60.20 in regular-session trading.

Key Numbers

  • EPS: $1.35 actual versus $1.10 estimated, a clear beat.

§ Product

  • How It Works
  • Custom Reports
  • AI Analyst
  • Intel Dashboard
  • Spark Charts
  • Trade Tracker
  • My Portfolio
  • Plans

§ Research

  • Main Feed
  • Community
  • Stock Reports
  • Macro Updates
  • Blog

§ Company

  • About Us
  • Contact

§ Fine Print

  • Terms of Service
  • Privacy Policy
  • Full Disclaimer
  • Cookie Policy

Notice: All content and data on TickerSpark is for informational purposes only and does not constitute financial or investment advice. All investments involve risk. Please see our Full Disclaimer for more details.

© 2026 Maxwell Cyberlogic LLC

Not Investment Advice

Made in Delaware, USA

Revenue: $13.07B actual versus $12.72B estimated, also ahead of forecasts.
  • Stock reaction: BMY closed at $60.20, down 0.61% from $60.57.
  • Trading range: Shares moved between $60.00 and $61.56 during the regular session.
  • Volume: 4,019,522 shares traded versus an average of 11,583,248.
  • EPS topped estimates in each of the five quarters listed from October 2025 through October 2026.

    • A Clean Beat Meets a Cautious Market

    BMY delivered a clean double beat. EPS and revenue both cleared analyst estimates, extending the company's EPS beat streak to five quarters. That points to steady execution against near-term forecasts.

    Still, the streak is not the same as a straight-line growth story. The latest $1.35 EPS was below the $2.04 reported on July 30. The quarter-to-quarter movement gives the earnings call an important job: explain how repeatable this execution is.

    The market reaction adds a second signal. Shares fell 0.61% despite the beat, while volume ran well below its average. The headline result alone did not reset short-term sentiment, so the forward outlook and the durability of recent results will carry more weight than the beat itself.

    Bottom line: BMY posted a strong double beat and a fifth straight EPS surprise, but the stock's decline keeps the market's verdict cautious.

    Read the full BMY research report
    ▌Common Questions

    Frequently asked questions

    +Did Bristol-Myers Squibb beat earnings estimates this quarter?
    Yes. Bristol-Myers Squibb reported $1.35 in EPS versus the $1.10 estimate and $13.07 billion in revenue versus $12.72 billion expected. That marked another quarter of outperformance and extended its EPS beat streak to five quarters.
    +Why did BMY stock fall after beating earnings?
    BMY slipped 0.61% to $60.20 despite the beat because the market appeared focused on the outlook and the durability of results, not just the headline numbers. The latest EPS of $1.35 was also well below the $2.04 reported in the prior quarter, which may have tempered enthusiasm.
    +How did Bristol-Myers Squibb's revenue compare with estimates?
    Revenue came in at $13.07 billion, ahead of the $12.72 billion consensus estimate. That was a modest top-line beat and helped support the company's double-beat quarter.
    +What was the trading reaction to BMY's earnings report?
    Shares closed at $60.20, down 0.61% from $60.57 in regular-session trading. Volume was 4,019,522 shares, well below the average of 11,583,248, showing a muted market reaction.
    ▌The Daily Briefing · Free

    A new stock idea, every evening.

    One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.

    Creates a free TickerSpark account — newsletter included.

    or with email

    Daily market recap + weekly preview. One-click unsubscribe in every email.

    ▌The Full Report

    Want the full picture on BMY?

    The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.

    Read the BMY report →Get Full Access →

    Not ready to subscribe? ·

    ▌The Full Report

    Get the full BMY research report

    • Analyst-grade deep dive
    • Charts, valuation, grades
    • Buy/sell price targets
    Read the BMY report →
    ▌For Active Investors

    Smarter research, on every ticker

    • Daily market intelligence
    • On-demand stock analysis
    • AI analyst chat
    Get Full Access →

    Cancel anytime

    ▌The Daily Briefing · Free

    A new stock idea, every evening.

    One stock worth watching each weekday, free in your inbox.

    Creates a free TickerSpark account — newsletter included.

    or with email

    Daily market recap + weekly preview. One-click unsubscribe in every email.

    ▌More on BMY

    More to read

    All articles
    Bristol-Myers Squibb Company (BMY) Gains After Deep Q3 Earnings
    BMY

    Bristol-Myers Squibb Company (BMY) Gains After Deep Q3 Earnings

    Bristol-Myers Squibb Company (BMY) gains after a deep Q3 earnings review showing beats on EPS and revenue, stronger growth-brand sales, and raised revenue guidance. The analysis also weighs margin pressure, lower EPS guidance, and the ongoing shift away from legacy products.

    Oct 29·7 min
    Bristol-Myers Squibb (BMY): Cash Flow and Growth Portfolio Support
    BMY

    Bristol-Myers Squibb (BMY): Cash Flow and Growth Portfolio Support

    Bristol-Myers Squibb combines strong cash generation with a broadening growth portfolio, but legacy-product dependence and debt keep the story balanced. The stock looks attractive on valuation, with Eliquis and newer launches helping offset patent pressure.

    Oct 29·19 min
    Trane Slides Despite Strong Bookings and Backlog Growth

    Trane Slides Despite Strong Bookings and Backlog Growth

    Earnings season delivered a split verdict as several companies beat estimates, but investors reacted unevenly. Trane Technologies sank despite 20% organic bookings growth, while Mastercard, Linde, Starbucks, Exxon Mobil and Dominion Energy posted solid results that drew more favorable market responses.

    Oct 31·7 min